Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759317 · ClinicalTrials.gov registry record · Phase 4
Physiologic Monitoring of Antidepressant Treatment Response
A Phase 4 study of Depression, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT00759317 is a Phase 4 study of Depression that has completed, run by University of California, Los Angeles. The registered enrollment target is 37 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00759317, a Phase 4 study of Depression, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
Study Objectives: * to identify neurophysiologic effects of venlafaxine treatment in normal controls using quantitative EEG (QEEG) cordance * to examine the effects of venlafaxine on different rating scales measuring mood and anxiety (e.g., Ham-D, BDI, SCL-90, POMS-BI, Visual Analog Mood Scale, SSRS, SASS, Q-LES-Q and SF-36) as well as on measures of cognitive and psychosocial function (i.e., Stroop, PASAT, RAVLT, Trailmaking A and B, Digit-Symbol, Grooved Pegboard, Multidimensional Health Locus of Control, Temperament and Character Inventory, Interpersonal Support Evaluation List, Godin Leisure-Time Questionnaire, and Pittsburgh Sleep Quality Index) in normal control subjects, and the association of changes in cordance with changes in thinking and memory. * to identify physiologic effects of venlafaxine treatment in normal controls using heart rate and immune function measures
Conditions Studied
Interventions
- DRUG venlafaxine (Effexor)
Study Locations (1)
California
- UCLA Laboratory of Brain, Behavior, and Pharmacology - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2001-06 |
| Est. Completion | 2002-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759317
The ClinicalTrials.gov registry entry for NCT00759317 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which venlafaxine (Effexor) is the first listed.
NCT00759317 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00759317 about?
NCT00759317 is a clinical study titled "Physiologic Monitoring of Antidepressant Treatment Response". Study Objectives: * to identify neurophysiologic effects of venlafaxine treatment in normal controls using quantitative EEG (QEEG) cordance * to examine the effects of venlafaxine on different rating scales measuring mood and anxiety (e.g., Ham-D, BDI, SCL-90, POMS-BI, Visual Analog Mood Scale, SSR...
What is the current status of trial NCT00759317?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2001-06. Estimated completion is 2002-09.
What conditions does trial NCT00759317 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00759317?
The interventions under investigation include: venlafaxine (Effexor) (DRUG).
Who is sponsoring clinical trial NCT00759317?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00759317 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.